

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

NCT05568719

Status	RECRUITING
Phase	Phase 3
Sponsor	Pfizer
Enrollment	173 participants

Key Eligibility Criteria

Inclusion (1)

- Only participants who received investigational giroctocogene fitelparvovec or fidanacogene eleparvovec and were enrolled in a Pfizer-sponsored study (C0371002, C0371003, C0371005, C3731001, C3731003) are eligible.

Exclusion (1)

- None

Locations (16 total)

The Regents of the University of California||UC Davis Health, Rancho Cordova, California, United States
UC Davis Health, Sacramento, California, United States
UC Davis Ambulatory Care Clinic, Sacramento, California, United States
... and 13 more locations